Sanofi-Aventis Zimulti (correction)
Executive Summary
Zimulti (rimonabant) is a CB-1 receptor antagonist; a recent article in "The Pink Sheet" mischaracterized the product. Rimonabant is "approvable" at FDA for obesity and "not approvable" for smoking cessation (1"The Pink Sheet" May 7, 2007, p. 25)...
You may also be interested in...
Acomplia’s Large European Cash Market Not Affecting Dropout Rate – Sanofi
A substantial portion of European patients purchasing Sanofi-Aventis' Acomplia pay entirely out-of-pocket for the obesity drug
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.